Comprehensive HIV Prevention Package for MSM in Port Elizabeth

HIV Clinical Trial

Official title:

Comprehensive HIV Prevention Package for MSM in Port Elizabeth

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02449733
• Other study ID #: IRB00079727
• Status: Completed
• Phase: N/A
• First received: May 18, 2015
• Last updated: July 4, 2017
• Start date: May 2015
• Est. completion date: March 2017

Study information

• Verified date: July 2017
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the acceptability and uptake of a combination package of biomedical, behavioral and community-level HIV prevention interventions and services for men who have sex with men (MSM) in South Africa.

Description:

The objective of the Sibanye Health Project is to develop and evaluate a combination package of biomedical, behavioral and community-level HIV prevention interventions and services for men who have sex with men (MSM) in Africa. Experience implementing the prevention interventions and preliminary data collected regarding the acceptability of the HIV prevention package will be used to develop a proposal to design a larger efficacy trial to test the combination HIV prevention package for MSM.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: March 2017
• Est. primary completion date: October 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male sex at birth

• Anal sex with another man in the past 12 months

• 18 years of age or older

• Resident of the study city, Port Elizabeth

• Able to complete study instruments, with or without assistance, in English, Xhosa or Afrikaans

• Willing to provide contact information

• Has a phone

Exclusion Criteria:

• Not male sex at birth

• No self-reported anal sex with a man in the past 12 months

• Less than 18 years of age

• Not a resident of the study city

• Plans to move from the study city within the year after enrollment

• Not able to complete study instructions, with or without assistance, in English, Xhosa or Afrikaans

• Not willing to provide contact information

• Does not have a phone

Additional Inclusion and Exclusion Criteria for participants on PrEP:

PrEP Inclusion Criteria:

• Identified as high-risk for HIV by the provider by meeting one or more of the criteria below:

• Have multiple partners

• Engage in transactional sex, including sex workers

• Use or abuse drugs

• Drink alcohol heavily

• Had more than 1 episode of a STI in the last year

• Is the HIV-negative partner in a discordant relationship, especially if the HIV-positive partner is not on antiretroviral therapy (ART)

• Is in a non-monogamous concordant relationship with a HIV-negative partner

• Is unable or unwilling to achieve consistent use of male condoms

• No contra-indications to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)

• Calculated creatinine clearance of at least 60 mL/min

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 x upper limit of normal (ULN)

• Hepatitis B surface antigen (HBsAg) negative

• Motivated to follow PrEP prescribing guidelines

• Willing to adhere to daily oral dosing

• Willing to attend PrEP maintenance visits every 3 months

PrEP Exclusion Criteria:

• HIV positive

• Signs or symptoms suggestive of acute HIV infection

• Have baseline creatinine clearance <60 ml/min

• Are unwilling to follow PrEP prescribing guidelines

• Are unwilling to attend PrEP maintenance visits every 3 months

• Are known to have hypertensives or diabetes

• Are hepatitis B susceptible (test HBsAg and HBsAb negative) and refuse to take a hepatitis B vaccine series

• Any contraindication to taking FTC/TDF

• Proteinuria 2+ or greater at screening

• Glucosuria 2+ or greater at screening

• Use of antiretroviral (ARV) therapy (e.g., for PEP or PrEP) in the 90 days prior to study entry

Related Conditions & MeSH terms

• HIV

Intervention

Behavioral:
• Condom choices
Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
• Condom-compatible lubricant choices
Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
• Couples HIV counseling and testing (CVCT)
Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.

Drug:
• Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF). For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit.

Other:
• HIV Testing
Rapid HIV testing at multiple time points
• Linkage to care
Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.

Procedure:
• Post-exposure prophylaxis (PEP)
Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.

Behavioral:
• Risk-reduction counseling
Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.

Locations

Country	Name	City	State
South Africa	Human Sciences Research Council	Port Elizabeth

Sponsors (1)

Lead Sponsor	Collaborator
Emory University

Country where clinical trial is conducted

South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retention in the cohort	Will assess the ability of the study to retain participants for full study period. This will be measured by the proportion of enrolled participants who attend all subsequent study visits through the 12-month visit.	12 months
Primary	Use of PrEP	Will assess uptake of PrEP by study participants. This will be measured as the proportion of enrolled participants eligible for PrEP at the 3 and 6-month study visits who choose to initiate PrEP at those visits.	6 months
Primary	Incident HIV infection	This will be measured as the number of seroconversions during follow-up among those who are HIV-uninfected at baseline.	12 months
Secondary	Condom use	Measured as the proportion of anal intercourse that is protected by condoms in the prior 3 months as self-reported reported in the questionnaire at each study visit.	3 months
Secondary	Lubricant use	Measured as the proportion of condom-protected anal intercourse in the prior for 3 months for which condom-compatible lubricant is used as self-reported in the questionnaire at each study visit.	3 months
Secondary	VCT and CVCT uptake	Measured as the number of times participants report HIV testing in the study period as part of the study visits and outside study visits compared to the number of time participants reported HIV testing in the year prior at baseline.	12 months
Secondary	Serodiscordant unprotected anal intercourse (UAI)	Measured as self-reported UAI in the last 3 months with a partner of positive or unknown HIV status as self-reported in the questionnaire at each study visit, pre- and post-intervention.	3 months
Secondary	Acceptability of PEP	Measured as the proportion of men who report an eligible exposure who accept and initiate PEP.	12 months
Secondary	MSM-specific provider training	Measured as the proportion of providers who are offered training who accept the training.	12 months